Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
66.62
+0.39 (0.59%)
At close: Dec 5, 2025, 4:00 PM EST
71.71
+5.09 (7.64%)
After-hours: Dec 5, 2025, 7:52 PM EST
Kymera Therapeutics Stock Forecast
Stock Price Forecast
According to 19 professional analysts, the 12-month price target for Kymera Therapeutics stock ranges from a low of $52 to a high of $90. The average analyst price target of $69.58 forecasts a 4.44% increase in the stock price over the next year.
Price Target: $69.58 (+4.44%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kymera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 8 | 9 | 10 |
| Buy | 7 | 7 | 7 | 8 | 9 | 9 |
| Hold | 2 | 2 | 2 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 17 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $68 → $80 | Strong Buy | Maintains | $68 → $80 | +20.08% | Nov 26, 2025 |
| Barclays | Barclays | Buy Maintains $60 → $70 | Buy | Maintains | $60 → $70 | +5.07% | Nov 5, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $53 → $69 | Buy | Maintains | $53 → $69 | +3.57% | Nov 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $70 → $84 | Strong Buy | Maintains | $70 → $84 | +26.09% | Nov 5, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $90 | Strong Buy | Initiates | $90 | +35.09% | Nov 3, 2025 |
Financial Forecast
Revenue This Year
56.87M
from 47.07M
Increased by 20.81%
Revenue Next Year
51.01M
from 56.87M
Decreased by -10.31%
EPS This Year
-3.54
from -2.98
EPS Next Year
-3.89
from -3.54
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 110.3M | 105.0M | ||||
| Avg | 56.9M | 51.0M | ||||
| Low | 38.2M | 9.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 134.2% | 84.6% | ||||
| Avg | 20.8% | -10.3% | ||||
| Low | -18.8% | -82.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.91 | -3.14 | ||||
| Avg | -3.54 | -3.89 | ||||
| Low | -3.78 | -5.88 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.